Cholesterol Absorption Inhibitors ICD-10 / CPT Cheatsheet (Women's Guide to Ezetimibe Billing and Clinical Use)

Why This Cheatsheet Exists and Who It Is For

Billing for lipid management in a women's-health practice is messier than most clinicians expect. You are often coding across overlapping diagnoses: a 34-year-old with PCOS and dyslipidemia, a 51-year-old whose LDL-C spiked 15 mg/dL after her last menstrual period, a 28-year-old with familial hypercholesterolemia who just found out she is pregnant. Each scenario carries its own ICD-10 principal diagnosis, possible secondary codes, and CPT billing considerations.

This guide is written for the clinician prescribing ezetimibe in a women's-health or primary-care setting, and for the woman patient who wants to understand why her chart says "E78.00" and what the drug is actually doing in her body. The coding tables below are paired with clinical notes so the right code gets matched to the right woman at the right life stage.

ICD-10 Codes for Cholesterol Absorption Inhibitor Prescribing

The correct ICD-10 code determines prior-authorization success, coverage of ezetimibe, and co-pay tier. Get it wrong and you are looking at a denial.

Core Lipid Disorder Codes

| ICD-10 Code | Description | When to Use in a Women's-Health Visit | |---|---|---| | E78.00 | Pure hypercholesterolemia, unspecified | Elevated LDL-C, normal TG, no secondary cause identified | | E78.01 | Familial hypercholesterolemia | LDL-C >190 mg/dL + family history; relevant in reproductive-age women who need teratogen counseling | | E78.1 | Pure hypertriglyceridemia | TG >200 mg/dL; ezetimibe has minimal TG effect, document secondary agent separately | | E78.2 | Mixed hyperlipidemia | Elevated LDL-C AND elevated TG; common in PCOS and insulin-resistant women | | E78.5 | Hyperlipidemia, unspecified | Use when lipid subtype not yet fully characterized or awaiting fasting labs | | E78.41 | Elevated lipoprotein(a) | Increasingly relevant in women; Lp(a) >50 mg/dL doubles ASCVD risk | | E78.49 | Other hyperlipidemia | Mixed picture not captured above |

Secondary-Cause Codes to Add as Additional Diagnoses

Women frequently present with dyslipidemia driven by an underlying condition. Always code the secondary cause when it is the reason you are treating lipids.

| ICD-10 Code | Description | Notes | |---|---|---| | E28.2 | Polycystic ovarian syndrome | PCOS raises LDL-C, lowers HDL-C, raises TG; code first | | E03.9 | Hypothyroidism, unspecified | TSH-driven dyslipidemia; treat thyroid first before adding ezetimibe | | E11.65 | Type 2 diabetes with hyperglycemia | Insulin resistance worsens lipid profile | | Z87.891 | Personal history of ASCVD | Documents secondary-prevention indication | | Z82.49 | Family history of ischemic heart disease | Supports statin + ezetimibe combination | | N95.1 | Menopausal and female climacteric states | Menopause-associated LDL-C rise; pairs with E78.00 or E78.5 | | Z79.890 | Hormone replacement therapy status | Document HRT when relevant to lipid discussion |

Familial Hypercholesterolemia: A Special Note for Women of Reproductive Age

Familial hypercholesterolemia (FH) affects roughly 1 in 250 people and is severely undertreated in women, who are often diagnosed later than men. If you are coding E78.01, you must also document contraception status, because statins (the backbone of FH treatment) are teratogenic. Ezetimibe is added to statin therapy in FH when LDL-C remains >100 mg/dL, per ACC/AHA 2018 guidelines. The coding pair E78.01 + Z79.3 (long-term use of hormonal contraceptives) signals to the payer that you have done the safety work.

CPT Codes for Ezetimibe-Related Visits and Lab Work

Laboratory CPT Codes

| CPT Code | Description | Frequency Notes | |---|---|---| | 80061 | Lipid panel (total cholesterol, HDL-C, TG, calculated LDL-C) | Baseline; repeat 4-12 weeks after starting ezetimibe | | 82465 | Cholesterol, serum, total | Standalone if full panel not needed | | 83718 | HDL-C | Standalone | | 84478 | Triglycerides | Standalone | | 83721 | LDL-C, direct measurement | Use when TG >400 mg/dL makes Friedewald calculation unreliable | | 86141 | CRP, high-sensitivity | Add-on for ASCVD risk stratification | | 83695 | Lipoprotein(a) | Order once; does not change with ezetimibe therapy | | 84443 | TSH | Rule out hypothyroidism as secondary cause, especially postpartum or perimenopausal |

Evaluation and Management CPT Codes

The E/M level depends on medical decision-making (MDM) complexity, not time, under the 2023 AMA E/M guidelines.

| CPT Code | MDM Level | Typical Ezetimibe Visit Type | |---|---|---| | 99213 | Low complexity | Stable hyperlipidemia, refill visit, labs reviewed | | 99214 | Moderate complexity | New diagnosis, medication adjustment, PCOS comorbidity, pregnancy planning counseling | | 99215 | High complexity | FH with cardiovascular event, complex polypharmacy, pregnancy with lipid disorder requiring specialist input | | 99401-99404 | Preventive counseling | Standalone diet/lifestyle counseling, not a separate E/M; bill with modifier -25 if same day as E/M |

Prior Authorization Tips for Ezetimibe in Women

Most commercial payers require a statin trial before covering ezetimibe as a separate agent. The combination pill ezetimibe/simvastatin (Vytorin) has its own prior-auth pathway. For women who are statin-intolerant (myalgia affects women at a higher rate than men), document:

• The specific statin tried (name, dose, duration).
• The symptom that caused discontinuation (CK level if measured).
• The ICD-10 code T46.6X5A (adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter) or M79.3 (panniculitis, use M79.89 for myalgia) alongside E78.00.

Statin-intolerance documentation is the single most common reason a prior-authorization appeal succeeds for ezetimibe monotherapy.

Sex-Specific Physiology: Why Ezetimibe Works Differently in Women

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the intestinal brush border, reducing cholesterol absorption by approximately 54%. The drug also acts on NPC1L1 in the liver's canalicular membrane. This mechanism is not sex-specific at the molecular level, but several downstream factors create real clinical differences for women.

Pharmacokinetics in Women

Ezetimibe undergoes rapid glucuronidation to its active metabolite, ezetimibe-glucuronide. A population pharmacokinetic analysis found that women have modestly higher ezetimibe-glucuronide AUC values than men at the same 10 mg dose, likely due to differences in UGT1A3 activity. Despite this, the 10 mg daily dose is used for all adults regardless of sex, because the LDL-C lowering response is comparable and dose-related adverse effects are not meaningfully elevated. No dose adjustment is currently recommended by FDA labeling.

The Menstrual Cycle and Lipid Fluctuation

LDL-C is not static across the menstrual cycle. Small studies show LDL-C and total cholesterol are modestly lower in the follicular phase and peak in the luteal phase, a range of roughly 8-15 mg/dL within the same woman across one cycle. This matters for timing your baseline lipid panel: draw it on days 1-7 of the cycle when feasible, or simply note the cycle day on the lab requisition so you interpret the result in context.

Perimenopause: The LDL-C Inflection Point

The menopausal transition is when many women cross the threshold for pharmacologic lipid treatment for the first time. Data from the Study of Women's Health Across the Nation (SWAN) showed LDL-C rises an average of 10.5 mg/dL across the menopause transition, independent of aging or weight gain. HDL-C also falls modestly. This is the life stage where ezetimibe, added to lifestyle change or a low-dose statin, may be enough to bring LDL-C below the goal of <100 mg/dL (or <70 mg/dL in high-risk women) without escalating to higher statin doses that carry greater myopathy risk in older women.

Ezetimibe in Women with PCOS

PCOS affects 8-13% of reproductive-age women and is one of the most common reasons a younger woman ends up needing lipid therapy. The dyslipidemia of PCOS is characterized by elevated small-dense LDL particles, elevated TG, and low HDL-C, even when standard LDL-C on a basic panel looks acceptable.

Ezetimibe does not treat insulin resistance directly, and it will not move the needle much on TG in isolation. The preferred approach in PCOS with dyslipidemia is:

1. Address insulin resistance first (metformin, inositol supplementation, dietary carbohydrate reduction, GLP-1 agonists where appropriate).
2. Add a statin if LDL-C remains elevated or ASCVD risk is intermediate or higher.
3. Add ezetimibe when LDL-C goal is not reached on maximally tolerated statin dose.

Code the visit E28.2 as the primary diagnosis if PCOS is the reason you are managing the lipids. E78.2 or E78.5 are secondary codes.

WomanRx PCOS Lipid Coding Framework: For a PCOS patient presenting for dyslipidemia management, the billing string that best reflects medical necessity and supports prior authorization for ezetimibe is:

• Primary: E28.2 (PCOS)
• Secondary: E78.2 or E78.00 (specific lipid disorder)
• Secondary: E11.65 or E11.9 (if type 2 diabetes or insulin resistance with diabetes code applies)
• CPT: 99214 (moderate MDM) + 80061 (lipid panel) + 84443 (TSH if not checked in past 12 months)

This combination documents the clinical rationale for lipid treatment at a younger-than-typical age, which payers scrutinize.

The IMPROVE-IT Trial: What the Evidence Actually Shows

The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) is the key cardiovascular outcomes trial for ezetimibe. It enrolled 18,144 patients with recent acute coronary syndrome, randomized to simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg, and followed them for a median of 6 years.

Key results:

• LDL-C in the combination group reached a median of 53.7 mg/dL vs 69.5 mg/dL in the statin-only group.
• The primary endpoint (major cardiovascular events) occurred in 32.7% vs 34.7%, an absolute risk reduction of 2.0% and hazard ratio of 0.936 (95% CI 0.89-0.99).
• Benefit was consistent across pre-specified subgroups, including women and patients with diabetes.

Women made up approximately 24% of the IMPROVE-IT population, which is a genuine limitation. Post-hoc analyses showed similar relative risk reduction in women, but the confidence intervals were wider because of the smaller sample. This is a known evidence gap you should discuss with your patient: the "18% LDL-C reduction" figure your patient will read on drug information leaflets comes largely from trials with male-majority populations. The mechanism is the same, but we are extrapolating to women more than we are reading from direct female-majority trial data.

Pregnancy, Lactation, and Contraception: What Every Prescriber Must Document

Ezetimibe is contraindicated in pregnancy. This is not a theoretical concern. Cholesterol is required for fetal neural tube closure, adrenal development, and steroidogenesis. Any drug that substantially reduces cholesterol absorption poses a developmental risk during organogenesis.

Pregnancy Category and Human Data

The FDA withdrew the A-through-X letter category system in 2015, but ezetimibe's prior Category X designation reflects the underlying biology: animal studies showed skeletal malformations at doses relevant to the human therapeutic range, and no adequate controlled studies in pregnant women exist. The FDA Pregnancy and Lactation Labeling Rule (PLLR) language in the current label states: "Discontinue ezetimibe when pregnancy is recognized."

What to Do When a Patient on Ezetimibe Becomes Pregnant

1. Stop ezetimibe immediately upon confirmed intrauterine pregnancy.
2. If ezetimibe was combined with a statin, stop the statin as well. Statins are also contraindicated in pregnancy (FDA PLLR label language: may cause fetal harm).
3. For women with FH who require continued lipid lowering in pregnancy, bile acid sequestrants such as cholestyramine are the only lipid-lowering class with an acceptable pregnancy safety profile, though they are poorly tolerated.
4. Document the exposure date in the chart and refer to maternal-fetal medicine if first-trimester exposure occurred.

Lactation

Human breast milk transfer of ezetimibe has not been studied. Animal data show ezetimibe passes into rat milk. Because cholesterol is critical for infant brain development and the drug's effect on nursing infants is unknown, the FDA label advises against use while breastfeeding. The Drugs and Lactation Database (LactMed) concurs: avoid ezetimibe during lactation.

Contraception Requirement

Any woman of reproductive age prescribed ezetimibe (especially as part of a statin + ezetimibe regimen) should be counseled on the need for reliable contraception. Document this conversation. For women using ezetimibe as monotherapy who cannot tolerate statins, the contraception requirement still applies because stopping ezetimibe alone will not be adequate lipid protection during a pregnancy if LDL-C rebounds to FH-range levels.

Preferred contraception methods for women on statin + ezetimibe: non-hormonal IUD, combined OCP (which has its own LDL-C and TG effects to account for), or barrier methods.

Who Is Right for Ezetimibe (and Who Is Not), by Life Stage

Reproductive Years (18-40)

Good candidates:

• Women with FH who need LDL-C lowering beyond what a maximally tolerated statin achieves, and who are using reliable contraception.
• Women with PCOS and elevated LDL-C after lifestyle optimization.
• Women with statin myalgia who need some pharmacologic LDL-C lowering while off statins.

Not appropriate:

• Any woman actively trying to conceive.
• Women who are pregnant or breastfeeding.
• Women with LDL-C <100 mg/dL and low 10-year ASCVD risk (treat with lifestyle first).

Trying to Conceive and Periconception

Stop ezetimibe at least one full ovulatory cycle before planned conception. Counsel the patient that LDL-C may rise during that period. For women with FH, a maternal-fetal medicine consult before stopping treatment is reasonable.

Perimenopause (40s-early 50s)

Best use case for ezetimibe. LDL-C rises during the menopausal transition. Many perimenopausal women are already on a low-to-moderate intensity statin; adding ezetimibe 10 mg daily can add another 18-25% LDL-C reduction without increasing statin dose or myopathy risk. Pregnancy remains possible in perimenopause until 12 full months of amenorrhea, so contraception documentation remains necessary until postmenopause is confirmed.

Postmenopause

Cardiovascular risk rises sharply after menopause. Approximately 44% of postmenopausal women have total cholesterol >240 mg/dL. Ezetimibe as add-on therapy is well suited here. Drug interactions with menopausal hormone therapy are minimal: ezetimibe is not significantly metabolized by CYP3A4, so it does not interact with estrogen or progesterone preparations at the pharmacokinetic level. No contraception documentation is needed once menopause is confirmed.

Drug Interactions Relevant to Women's Health Medications

| Drug | Interaction with Ezetimibe | Clinical Action | |---|---|---| | Cyclosporine | Increases ezetimibe AUC by ~12-fold | Avoid combination; if unavoidable, use lowest effective ezetimibe dose and monitor closely | | Fenofibrate | Increases ezetimibe AUC ~1.5-fold | Combination is used for mixed hyperlipidemia; monitor for cholelithiasis | | Cholestyramine (bile acid sequestrant) | Reduces ezetimibe AUC by ~55% | Administer ezetimibe at least 2 hours before or 4 hours after cholestyramine | | Combined oral contraceptives | No significant PK interaction | Safe to combine; note OCP's own effect on TG and HDL-C separately | | Levothyroxine | No direct interaction | Treat hypothyroidism to TSH goal first; recheck lipids before adding ezetimibe |

Monitoring and Follow-Up: A Practical Schedule

After starting ezetimibe 10 mg daily, the expected LDL-C reduction appears within 2 weeks, but guideline-recommended reassessment is at 4-12 weeks for the first check, then annually if stable.

Suggested monitoring schedule:

• Week 0 (baseline): CPT 80061 (fasting lipid panel), 84443 (TSH if not recent), ALT if statin co-prescribed.
• Week 4-12: CPT 80061 (repeat lipid panel), E/M visit 99213-99214.
• Month 6 and annually: CPT 80061, HbA1c if diabetes or PCOS, annual E/M 99213-99215 depending on complexity.

Ezetimibe does not require routine liver function monitoring on its own. Liver enzyme elevation with ezetimibe monotherapy is rare and occurs at a rate comparable to placebo in clinical trials. When combined with a statin, follow the statin's monitoring protocol.

Documentation Language That Supports Medical Necessity

The following phrases, when included in your note, strengthen prior-authorization submissions and reduce claim denials:

• "Patient has documented statin intolerance with myalgia on [statin name] [dose] discontinued on [date]; CK measured [value] on [date]."
• "LDL-C remains above goal of [target] mg/dL on maximally tolerated statin therapy; ezetimibe 10 mg daily added per [ACC/AHA 2018 guideline] recommendation for high-risk patients not at LDL-C goal."
• "Patient is postmenopausal (LMP [date], confirmed by FSH [value]) with rising LDL-C; no contraception documentation required."
• "Patient of reproductive age counseled on ezetimibe teratogenicity; patient confirmed use of [contraception method]; documented in chart."

These phrases map directly to payer LCD (Local Coverage Determination) language for lipid-lowering therapy coverage.